Enochian BioSciences (NASDAQ: ENOB) is set to present its cutting-edge therapies for HIV, Hepatitis B, and Oncology at the H.C. Wainwright 22nd Annual Global Investment Conference. The presentation will occur on September 15, 2020, at 2:00 PM Eastern, led by Executive Vice Chair Dr. Mark Dybul. Investors are invited to join a live virtual session and can also participate in one-on-one meetings. Further details and a link to the webcast can be found on Enochian's website.
Enochian BioSciences announced a successful INTERACT meeting with the FDA regarding its innovative HIV treatment, ENOB-HV-01. The meeting highlighted alignment between Enochian's strategies and FDA feedback, marking a crucial step towards developing gene-modified cellular therapies. Dr. Mark Dybul, Executive Vice-Chair, expressed optimism about the pre-clinical work leading to a potential pre-IND submission in 2021. The INTERACT meeting represents a key early engagement for Enochian's regulatory pathway, aimed at addressing challenges in autologous stem cell transplantation and potential HIV cures.